NASDAQ:TNXP - Tonix Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.09 -0.01 (-0.32 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$3.09
Today's Range$3.02 - $3.17
52-Week Range$2.70 - $4.99
Volume49,848 shs
Average Volume88,739 shs
Market Capitalization$25.86 million
P/E Ratio-1.07
Dividend YieldN/A
Beta2.84

About Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals logoTonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TNXP
CUSIPN/A
Phone212-980-9155

Debt

Debt-to-Equity RatioN/A
Current Ratio8.76
Quick Ratio8.76

Price-To-Earnings

Trailing P/E Ratio-1.07
Forward P/E Ratio-1.16
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.23 per share
Price / Book1.39

Profitability

EPS (Most Recent Fiscal Year)($2.90)
Net Income$-21,120,000.00
Net MarginsN/A
Return on Equity-83.89%
Return on Assets-77.84%

Miscellaneous

Employees14
Outstanding Shares8,340,000

Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals (NASDAQ:TNXP) announced its quarterly earnings data on Monday, March, 12th. The company reported ($0.67) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.77) by $0.10. View Tonix Pharmaceuticals' Earnings History.

When is Tonix Pharmaceuticals' next earnings date?

Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Tonix Pharmaceuticals.

What price target have analysts set for TNXP?

6 brokers have issued 1 year price targets for Tonix Pharmaceuticals' stock. Their predictions range from $6.00 to $10.00. On average, they anticipate Tonix Pharmaceuticals' share price to reach $8.3333 in the next year. View Analyst Ratings for Tonix Pharmaceuticals.

Who are some of Tonix Pharmaceuticals' key competitors?

Who are Tonix Pharmaceuticals' key executives?

Tonix Pharmaceuticals' management team includes the folowing people:
  • Dr. Seth Lederman M.D., Co-Founder, Pres, CEO & Chairman (Age 60)
  • Dr. Donald W. Landry, Co-Founder & Director (Age 63)
  • Mr. Bradley Saenger CPA, CFO & Treasurer (Age 44)
  • Dr. Gregory M. Sullivan M.D., Chief Medical Officer & Sec. (Age 52)
  • Mrs. Jessica Edgar Morris, Chief Operating Officer

Has Tonix Pharmaceuticals been receiving favorable news coverage?

News articles about TNXP stock have trended somewhat positive on Saturday, Accern reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tonix Pharmaceuticals earned a news impact score of 0.05 on Accern's scale. They also gave media coverage about the company an impact score of 47.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $3.09.

How big of a company is Tonix Pharmaceuticals?

Tonix Pharmaceuticals has a market capitalization of $25.86 million. The company earns $-21,120,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Tonix Pharmaceuticals employs 14 workers across the globe.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVE. - SUITE 306, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]


MarketBeat Community Rating for Tonix Pharmaceuticals (TNXP)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tonix Pharmaceuticals (NASDAQ:TNXP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Tonix Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.3333, suggesting that the stock has a possible upside of 169.69%. The high price target for TNXP is $10.00 and the low price target for TNXP is $6.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.80
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.3333$8.3333$8.3333$8.3333
Price Target Upside: 169.69% upside117.01% upside117.01% upside159.61% upside

Tonix Pharmaceuticals (NASDAQ:TNXP) Consensus Price Target History

Price Target History for Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals (NASDAQ:TNXP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2018Brookline Cap MReiterated RatingBuyLowView Rating Details
5/1/2018Brookline Capital ManagementReiterated RatingBuyLowView Rating Details
12/1/2017AegisReiterated RatingBuyMediumView Rating Details
8/23/2017Dawson JamesReiterated RatingBuy$9.00MediumView Rating Details
8/22/2017Drexel HamiltonInitiated CoverageBuyHighView Rating Details
8/18/2017Roth CapitalUpgradeNeutral ➝ Buy$6.00HighView Rating Details
12/20/2016OppenheimerReiterated RatingHoldN/AView Rating Details
9/7/2016Cantor FitzgeraldDowngradeBuy ➝ HoldN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Tonix Pharmaceuticals (NASDAQ:TNXP) Earnings History and Estimates Chart

Earnings by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals (NASDAQ:TNXP) Earnings Estimates

2018 EPS Consensus Estimate: ($2.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.68)($0.68)($0.68)
Q2 20181($0.71)($0.71)($0.71)
Q3 20181($0.74)($0.74)($0.74)
Q4 20181($0.78)($0.78)($0.78)

Tonix Pharmaceuticals (NASDAQ TNXP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018        
5/16/2018Q1 2018($0.70)($0.88)ViewN/AView Earnings Details
3/12/2018Q4 2017($0.77)($0.67)ViewN/AView Earnings Details
11/7/2017Q3 2017($0.68)($0.70)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.78)($0.65)ViewN/AView Earnings Details
5/15/2017Q1 2017($1.36)($1.27)ViewN/AView Earnings Details
4/17/2017Q4 2016($1.77)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.34)($0.29)ViewN/AView Earnings Details
8/5/2016Q2 2016($5.60)($5.00)ViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.74)ViewN/AView Earnings Details
3/4/2016Q4($0.66)($0.71)ViewN/AView Earnings Details
11/9/2015Q3 2015($6.00)($6.70)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.73)ViewN/AView Earnings Details
5/11/2015Q115($0.54)($0.71)ViewN/AView Earnings Details
3/3/2015Q414($0.81)($0.83)ViewN/AView Earnings Details
11/10/2014Q314($0.69)($0.71)ViewN/AView Earnings Details
8/8/2014Q214($0.53)($0.61)ViewN/AView Earnings Details
5/13/2014Q114($0.35)($0.59)ViewN/AView Earnings Details
3/31/2014($0.46)($0.74)ViewN/AView Earnings Details
11/13/2013Q3 2013($5.60)($8.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Tonix Pharmaceuticals (NASDAQ:TNXP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Tonix Pharmaceuticals (NASDAQ TNXP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.12%
Institutional Ownership Percentage: 13.89%
Insider Trading History for Tonix Pharmaceuticals (NASDAQ:TNXP)
Institutional Ownership by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Tonix Pharmaceuticals (NASDAQ TNXP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/26/2017Seth LedermanCEOBuy5,300$3.61$19,133.0011,166View SEC Filing  
12/21/2017Ernest MarioDirectorSell36,967$3.51$129,754.1710,000View SEC Filing  
12/18/2017Ernest MarioDirectorSell10,000$3.57$35,700.0010,000View SEC Filing  
12/14/2017Ernest MarioDirectorSell1,967$3.58$7,041.8610,000View SEC Filing  
8/17/2017Seth LedermanCEOBuy20,000$3.00$60,000.0011,166View SEC Filing  
6/30/2017Ernest MarioDirectorSell6,105$4.28$26,129.4063,073View SEC Filing  
6/30/2017Seth LedermanCEOBuy5,000$4.33$21,650.007,912View SEC Filing  
6/26/2017Seth LedermanCEOBuy5,000$4.40$22,000.007,912View SEC Filing  
6/20/2017Seth LedermanCEOBuy20,000$4.22$84,400.007,912View SEC Filing  
11/23/2016Ernest MarioDirectorBuy120,000$0.41$49,200.00630,724View SEC Filing  
9/13/2016Ernest MarioDirectorBuy100,000$0.79$79,000.00530,724View SEC Filing  
6/22/2016Seth LedermanCEOBuy20,000$2.08$41,600.0080,815View SEC Filing  
6/21/2016Bradley SaengerCFOBuy2,000$2.00$4,000.006,039View SEC Filing  
6/21/2016Bruce DaughertyInsiderBuy100,000$2.00$200,000.0065,777View SEC Filing  
6/21/2016John B RhodesDirectorBuy25,000$2.00$50,000.00112,196View SEC Filing  
6/3/2016Gregory M SullivanInsiderBuy20,000$2.50$50,000.0043,185View SEC Filing  
5/12/2016Ernest MarioDirectorBuy31,042$2.30$71,396.60380,724View SEC Filing  
5/11/2016Ernest MarioDirectorBuy8,210$2.24$18,390.40349,682View SEC Filing  
3/23/2016Seth LedermanCEOBuy8,000$2.44$19,520.0080,815View SEC Filing  
3/16/2016Ernest MarioDirectorBuy75,000$2.29$171,750.00341,472View SEC Filing  
9/30/2015Gregory M SullivanInsiderBuy5,000$5.18$25,900.0016,925View SEC Filing  
9/28/2015Gregory M SullivanInsiderBuy4,694$5.95$27,929.3011,925View SEC Filing  
9/25/2015Seth LedermanCEOBuy6,000$6.50$39,000.0071,074View SEC Filing  
8/26/2015Ernest MarioDirectorBuy10,000$6.05$60,500.00260,472View SEC Filing  
8/25/2015Ernest MarioDirectorBuy1,468$6.40$9,395.20250,472View SEC Filing  
8/24/2015Ernest MarioDirectorBuy2,532$6.20$15,698.40249,004View SEC Filing  
8/20/2015Ernest MarioDirectorBuy6,000$6.64$39,840.00246,472View SEC Filing  
8/17/2015Ernest MarioDirectorBuy15,000$6.93$103,950.00View SEC Filing  
7/17/2015John B RhodesDirectorBuy6,000$7.50$45,000.00View SEC Filing  
7/17/2015Leland GershellCFOBuy1,000$7.50$7,500.00View SEC Filing  
6/11/2015Gregory M SullivanInsiderBuy4,500$8.38$37,710.00View SEC Filing  
3/17/2015Seth LedermanCEOBuy2,000$7.02$14,040.00View SEC Filing  
3/13/2015Seth LedermanCEOBuy2,000$7.24$14,480.00View SEC Filing  
3/11/2015Seth LedermanCEOBuy2,000$6.95$13,900.00View SEC Filing  
3/10/2015Charles E Iv MatherDirectorBuy1,000$6.80$6,800.00View SEC Filing  
3/9/2015Seth LedermanCEOBuy2,000$6.48$12,960.00View SEC Filing  
3/6/2015Ernest MarioDirectorBuy4,000$6.57$26,280.00View SEC Filing  
3/5/2015Seth LedermanCEOBuy2,000$6.27$12,540.00View SEC Filing  
2/9/2015Ernest MarioDirectorBuy30,000$5.85$175,500.00View SEC Filing  
2/9/2015Leland GershellCFOBuy5,000$5.85$29,250.00View SEC Filing  
9/27/2013Charles E Iv MatherDirectorBuy1,000$3.65$3,650.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tonix Pharmaceuticals (NASDAQ TNXP) News Headlines

Source:
DateHeadline
Tonix Pharma (TNXP) Reports Preliminary Results from Phase 1 Pivotal Multiple-Dose Bridging PK Study of Tonmya or TNX-102 SLTonix Pharma (TNXP) Reports Preliminary Results from Phase 1 Pivotal Multiple-Dose Bridging PK Study of Tonmya or TNX-102 SL
www.streetinsider.com - May 25 at 9:35 AM
Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SLTonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL
finance.yahoo.com - May 24 at 9:58 AM
Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical PsychopharmacologyTonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology
finance.yahoo.com - May 23 at 4:13 PM
BRIEF-Tonix Pharmaceuticals Holding Corp Enters Into Sales Agreement With Cowen And CoBRIEF-Tonix Pharmaceuticals Holding Corp Enters Into Sales Agreement With Cowen And Co
www.reuters.com - May 19 at 9:41 AM
-$0.70 Earnings Per Share Expected for Tonix Pharmaceuticals (TNXP) This Quarter-$0.70 Earnings Per Share Expected for Tonix Pharmaceuticals (TNXP) This Quarter
www.americanbankingnews.com - May 18 at 5:17 AM
Tonix Pharmaceuticals (TNXP) Announces Quarterly  Earnings Results, Misses Expectations By $0.18 EPSTonix Pharmaceuticals (TNXP) Announces Quarterly Earnings Results, Misses Expectations By $0.18 EPS
www.americanbankingnews.com - May 15 at 8:12 AM
BRIEF-Tonix Pharmaceuticals Posts Q1 Loss Of $0.88 Per ShareBRIEF-Tonix Pharmaceuticals Posts Q1 Loss Of $0.88 Per Share
www.reuters.com - May 14 at 11:06 AM
Tonix: 1Q Earnings SnapshotTonix: 1Q Earnings Snapshot
finance.yahoo.com - May 14 at 11:06 AM
Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs UpdateTonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update
finance.yahoo.com - May 14 at 11:06 AM
Tonix Is A Buy For Potentially Great Return On PTSD BreakthroughTonix Is A Buy For Potentially Great Return On PTSD Breakthrough
seekingalpha.com - May 11 at 10:51 AM
Tonix: PTSD Breakthrough Or Too Risky For Stockholders?Tonix: PTSD Breakthrough Or Too Risky For Stockholders?
seekingalpha.com - May 7 at 4:19 PM
Tonix Pharmaceuticals (TNXP) Scheduled to Post Quarterly Earnings on MondayTonix Pharmaceuticals (TNXP) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 7 at 3:14 AM
Brookline Cap M Reiterates "Buy" Rating for Tonix Pharmaceuticals (TNXP)Brookline Cap M Reiterates "Buy" Rating for Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - May 5 at 6:37 AM
Tonix Pharmaceuticals (TNXP) "Buy" Rating Reaffirmed at Brookline Capital ManagementTonix Pharmaceuticals' (TNXP) "Buy" Rating Reaffirmed at Brookline Capital Management
www.americanbankingnews.com - May 4 at 11:58 PM
Tonix Pharmaceuticals (TNXP) Buy Rating Reaffirmed at Brookline Cap MTonix Pharmaceuticals' (TNXP) Buy Rating Reaffirmed at Brookline Cap M
www.americanbankingnews.com - May 4 at 3:41 PM
Tonix Pharmaceuticals (TNXP) Receives Consensus Rating of "Buy" from AnalystsTonix Pharmaceuticals (TNXP) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 4 at 11:09 AM
Tonix Pharmaceuticals (TNXP) Given "Buy" Rating at Brookline Cap MTonix Pharmaceuticals (TNXP) Given "Buy" Rating at Brookline Cap M
www.americanbankingnews.com - May 4 at 10:07 AM
Tonix Pharmaceuticals Receives IND Clearance by US FDA for TNX-102 SL in Agitation in Alzheimers DiseaseTonix Pharmaceuticals Receives IND Clearance by US FDA for TNX-102 SL in Agitation in Alzheimer's Disease
globenewswire.com - May 3 at 4:15 PM
BRIEF-Tonix Pharmaceuticals Receives IND Clearance By US FDA For TNX-102 SLBRIEF-Tonix Pharmaceuticals Receives IND Clearance By US FDA For TNX-102 SL
www.reuters.com - May 3 at 4:15 PM
Tonix Pharmaceuticals (TNXP) Upgraded to Buy by ValuEngineTonix Pharmaceuticals (TNXP) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - May 2 at 3:48 PM
Tonix Pharma (TNXP) Receives IND Clearance by FDA for TNX-102 SL in Agitation in ADTonix Pharma (TNXP) Receives IND Clearance by FDA for TNX-102 SL in Agitation in AD
www.streetinsider.com - May 2 at 9:39 AM
Tonix on go with mid-stage study of TNX-102 SL in Alzheimers agitation; shares up 7% premarketTonix on go with mid-stage study of TNX-102 SL in Alzheimer's agitation; shares up 7% premarket
seekingalpha.com - May 1 at 9:41 AM
Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s DiseaseTonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease
finance.yahoo.com - May 1 at 9:41 AM
 Brokerages Anticipate Tonix Pharmaceuticals (TNXP) to Announce -$0.69 EPS Brokerages Anticipate Tonix Pharmaceuticals (TNXP) to Announce -$0.69 EPS
www.americanbankingnews.com - April 30 at 5:14 PM
Zacks: Analysts Expect Tonix Pharmaceuticals (TNXP) Will Post Earnings of -$0.69 Per ShareZacks: Analysts Expect Tonix Pharmaceuticals (TNXP) Will Post Earnings of -$0.69 Per Share
www.americanbankingnews.com - April 13 at 7:15 PM
Tonix Pharmaceuticals (TNXP) Presents At MicroCap Conference 2018 - SlideshowTonix Pharmaceuticals (TNXP) Presents At MicroCap Conference 2018 - Slideshow
seekingalpha.com - April 10 at 4:13 PM
Tonix Pharmaceuticals (TNXP) versus Its Peers Head to Head SurveyTonix Pharmaceuticals (TNXP) versus Its Peers Head to Head Survey
www.americanbankingnews.com - April 6 at 3:20 PM
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy ...Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy ...
globenewswire.com - April 5 at 4:14 PM
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference ...Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference ...
www.nasdaq.com - April 5 at 4:14 PM
Tonix Pharmaceuticals to present PTSD program at the MicroCap Conference in New YorkTonix Pharmaceuticals to present PTSD program at the MicroCap Conference in New York
seekingalpha.com - April 4 at 5:23 PM
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSDTonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
finance.yahoo.com - April 3 at 10:07 AM
ValuEngine Downgrades Tonix Pharmaceuticals (TNXP) to Strong SellValuEngine Downgrades Tonix Pharmaceuticals (TNXP) to Strong Sell
www.americanbankingnews.com - April 2 at 11:29 PM
Tonix Pharmaceuticals Holding Corp. (TNXP) Expected to Announce Earnings of -$0.69 Per ShareTonix Pharmaceuticals Holding Corp. (TNXP) Expected to Announce Earnings of -$0.69 Per Share
www.americanbankingnews.com - March 27 at 7:20 PM
Eyenovia Appoints Three Industry Veterans to Board of DirectorsEyenovia Appoints Three Industry Veterans to Board of Directors
finance.yahoo.com - March 26 at 4:18 PM
Zacks Investment Research Comments on Tonix Pharmaceuticals Holding Corp.s Q1 2018 Earnings (TNXP)Zacks Investment Research Comments on Tonix Pharmaceuticals Holding Corp.'s Q1 2018 Earnings (TNXP)
www.americanbankingnews.com - March 22 at 8:10 AM
Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL - GlobeNewswire (press release)Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL - GlobeNewswire (press release)
globenewswire.com - March 21 at 4:25 PM
Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SLTonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL
finance.yahoo.com - March 21 at 4:24 PM
TNXP: Phase 3 Trial in PTSD Nearing 50% Enrollment; Interim Analysis in 3Q18TNXP: Phase 3 Trial in PTSD Nearing 50% Enrollment; Interim Analysis in 3Q18
finance.yahoo.com - March 20 at 9:45 AM
Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural ... - GlobeNewswire (press release)Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 4:16 PM
Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering SymposiumTonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
finance.yahoo.com - March 13 at 11:27 AM
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 12 at 4:16 PM
Tonix Pharmaceuticals Holding Corp. (TNXP) Expected to Post Earnings of -$0.77 Per ShareTonix Pharmaceuticals Holding Corp. (TNXP) Expected to Post Earnings of -$0.77 Per Share
www.americanbankingnews.com - March 10 at 1:34 PM
Tonix Pharmaceuticals to Present at the 30th Annual ROTH ... - GlobeNewswire (press release)Tonix Pharmaceuticals to Present at the 30th Annual ROTH ... - GlobeNewswire (press release)
globenewswire.com - March 6 at 4:12 PM
Tonix Pharmaceuticals to Present at the 30th Annual ROTH ConferenceTonix Pharmaceuticals to Present at the 30th Annual ROTH Conference
feeds.benzinga.com - March 6 at 7:45 AM
Tonix Pharmaceuticals (TNXP) Upgraded by ValuEngine to "Hold"Tonix Pharmaceuticals (TNXP) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - March 4 at 2:24 PM
-$0.77 Earnings Per Share Expected for Tonix Pharmaceuticals Holding Corp. (TNXP) This Quarter-$0.77 Earnings Per Share Expected for Tonix Pharmaceuticals Holding Corp. (TNXP) This Quarter
www.americanbankingnews.com - February 21 at 7:10 PM
Tonix Pharmaceuticals (TNPX) Presents At BIO CEO & Investor Conference - SlideshowTonix Pharmaceuticals (TNPX) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:21 PM
Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO ... - GlobeNewswire (press release)Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 5:54 AM
Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York CityTonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City
finance.yahoo.com - February 8 at 5:54 AM
Tonix Pharmaceuticals to Present at Noble Capital Markets Fourteenth Annual Investor Conference in Fort Lauderdale - GlobeNewswire (press release)Tonix Pharmaceuticals to Present at Noble Capital Markets' Fourteenth Annual Investor Conference in Fort Lauderdale - GlobeNewswire (press release)
globenewswire.com - January 26 at 3:20 PM

SEC Filings

Tonix Pharmaceuticals (NASDAQ:TNXP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Tonix Pharmaceuticals (NASDAQ:TNXP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tonix Pharmaceuticals (NASDAQ TNXP) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.